Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017 (2017), Article ID 4387081, 9 pages
Research Article

Expression and Clinical Significance of ILF2 in Gastric Cancer

1Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China
2Department of Cardiology, Tianjin People’s Hospital, Tianjin, China
3Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China

Correspondence should be addressed to Dong-feng Yu

Received 21 March 2017; Revised 30 May 2017; Accepted 2 July 2017; Published 31 July 2017

Academic Editor: Yuen Yee Cheng

Copyright © 2017 Zi-huan Yin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The aim of this study is to investigate the expression levels and clinical significance of ILF2 in gastric cancer. The mRNA and protein expression levels of ILF2 were, respectively, examined by quantitative real-time PCR (qRT-PCR) and Western blot from 21 paired fresh frozen GC tissues and corresponding normal gastric tissues. In order to analyze the expression pattern of ILF2 in GC, 60 paired paraffin-embedded GC slides and corresponding normal gastric slides were detected by immunohistochemistry (IHC) assay. The correlation between ILF2 protein expression levels and clinicopathological parameters, overall survival (OS), disease-free survival (DFS), and clinical prognosis were analyzed by statistical methods. Significantly higher levels of ILF2 were detected in GC tissues compared with normal controls at both mRNA and protein level. High expression of ILF2 was tightly correlated with depth of invasion, lymph node metastasis, pathological stage, and histological differentiation. Log-rank test showed that high expression of ILF2 was positively associated with poor clinical prognosis. Multivariate analysis identified that ILF2 was an independent prognostic factor for OS and DFS. Our findings suggest that ILF2 may be a valuable biomarker and a novel potential prognosis predictor for GC patients.